---
title: "B4GALT3"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# Gene Information Analysis for B4GALT3 Gene"
tags: ['GeneB4GALT3', 'Galactosyltransferase', 'Glycosphingolipids', 'FabryDisease', 'EnzymeReplacementTherapy', 'Migalastat', 'Biomarkers', 'TreatmentOutcomes']
---

# Gene Information Analysis for B4GALT3 Gene

## Gene Function
B4GALT3 gene encodes for an enzyme Galactosyltransferase which is important for the biosynthesis of glycosphingolipids called globosides.

## Gene External IDs
- Gene ID: 8703
- Genomic Location: Chromosome 1q42.1
- Aliases: B4Gal-T3, Gb3 synthase, Gb3S, BETA4Gal-T3

## Gene External Sites
- HGNC: 947
- NCBI Entrez: 8703
- Ensembl: ENSG00000132694
- OMIM: 606983
- UniProtKB/Swiss-Prot: O60513

## AA Mutation List
- p.Gln279Arg (rs149142359)
- p.Gln279Glu (rs149142359) 

## Somatic SNVs/InDels
- c.1105C>T (rs201972468)
- c.1105C>A (rs199585118)
- c.1106G>A (rs199985828)

## Related Disease
- Fabry Disease (FD)

## Treatment and Prognosis
- Enzyme Replacement Therapy (ERT) and Substrate Reduction Therapy (SRT) are available with limited success.
- Prognosis may vary depending on the severity of the condition and treatment response.

## Drug Response
- Migalastat (Galafold) is an approved medication for FD patients with a specific genetic mutation in the B4GALT3 gene.

## References
- Subject: B4GALT3 protein
- Author: Matsuda, Junko
- DOI: 10.3390/ijms22010085
- Title: Potential Application of Glycosphingolipids as Biomarkers for Cancers and Other Diseases
- Subject: Fabry Disease
- Author: Goker-Alpan, Ozlem
- DOI: 10.1146/annurev-paed-090315-090244
- Title: Long-Term Outcomes of Fabry Disease Patients with Treatment Initiated During Childhood or Adulthood

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**